COrtical Superficial Siderosis and REcurrent Lobar Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in the elderly with high risk of recurrence. The investigators aim to determine the relationship between cortical superficial siderosis (cSS), a MRI hemorrhagic marker of CAA and the risk of symptomatic ICH recurrence in a multicentric prospective cohort of patients with acute lobar ICH related to CAA. The investigators hypothesize that patients with cSS have an increased risk of recurrent symptomatic ICH relative to those without cSS.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Healthy Volunteers: f
View:

• Lobar ICH within 30 days after onset

• Available brain MRI sequences of adequate quality including fluid-attenuated inversion recovery (FLAIR) and T2\*-weighted gradient-recalled echo (T2\*-GRE) sequences.

• Modified Boston criteria for probable or possible CAA

• Age ≥ 55 years

• Written consent

Locations
Other Locations
France
Pellegrin Hospital
RECRUITING
Bordeaux
Gui de Chauliac Hospital
NOT_YET_RECRUITING
Montpellier
Lariboisière Hospital
RECRUITING
Paris
CHU Purpan. Hôpital Pierre-Paul Riquet
RECRUITING
Toulouse Cedex 9
Contact Information
Primary
Nicolas RAPOSO, MD
raposo.n@chu-toulouse.fr
5 61 77 76 40
Time Frame
Start Date: 2018-10-12
Estimated Completion Date: 2025-02
Participants
Target number of participants: 170
Treatments
Other: Patients with cortical superficial siderosis.
During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
Other: Patients without cortical superficial siderosis
During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
Sponsors
Leads: University Hospital, Toulouse

This content was sourced from clinicaltrials.gov